Background
==========

*ADAM33*, a disintegrin and metalloproteinase 33 has been the first gene published, which had been identified by positional cloning as a putative candidate gene for the development of asthma and bronchial hyperresponsiveness \[[@B1]\]. It has been speculated that the *ADAM33*gene, expressed in airway smooth muscle cells and fibroblasts of the lung, codes for a protein important for cell fusion, cell adhesion, cell signalling and proteolysis. Furthermore, ADAM33 was suggested to play a role in airway remodeling \[[@B2]\].

The *ADAM33*gene is located on chromosome 20p13 and 37 SNPs have initially been identified \[[@B1]\]. Ever since the first report of association between *ADAM33*polymorphisms and asthma in two Caucasian populations from the UK and the USA, a number of replication studies have been published with very diverse results. Various associations between different asthma phenotypes as well as with BHR and several different SNPs in the gene have been reported \[[@B3]-[@B7]\]. One possible explanation for this diversity in replication results could be the heterogeneity between study populations or between the definitions of asthma in different study populations. It can be hypothesized that ADAM33, involved in remodeling, may be especially important in some specific forms of asthma. Thus, it may be more relevant in adult or non-atopic than in atopic asthma. Furthermore, it may affect lung function more than atopy status. Finally, environmental factors such as passive smoke exposure could potentially interact with ADAM33 in exerting its remodeling function in the lung as ADAM33 also seems to be involved in COPD mediated processes\[[@B8]\].

We tested the hypothesis that the *ADAM33*gene is associated with atopic or non atopic asthma, lung function and BHR in a large nested case control study of German children (N = 1,872; comparing 624 asthmatics and/or BHR positives and 1,248 non-asthmatic, BHR negative, non-atopic controls) and a German multicentre family based birth cohort study (MAS) (888 children with DNA available, 96 asthmatics and 792 non-asthmatics). The effect of ten SNPs spanning the ADAM33 gene as indicated in figure [1](#F1){ref-type="fig"}, previously showing associations with asthma phenotypes in some populations, and haplotypes of these SNPs were analysed.

![**Position of the genotyped polymorphisms (SNPs) in the ADAM33 gene in respect to the 22 exons (blue) and untranslated regions (red) of the gene**. SNPs nomenclature according to the initial report by Van Eerdewegh et al. and alternatively according to the rs system in brackets.](1465-9921-7-91-1){#F1}

Methods
=======

Description of the case control study population
------------------------------------------------

Between 1995 and 1996, cross sectional studies were conducted in Munich (ISAAC II), Dresden (ISAAC II) and Leipzig to assess the prevalence of asthma and allergies in schoolchildren age 9 to 11 years \[[@B9],[@B10]\]. As the populations and phenotyping methods have been described in detail before \[[@B9]\], only an overview of the methods pertaining to this analysis is given here. Parental questionnaires for self-completion were sent through the schools to the families including the ISAAC core questions while slightly different questionnaires were used for the Leipzig population \[[@B9]\]. All children in the three cities whose parents reported that a doctor diagnosed \"asthma\" at least once or \"asthmatic, spastic or obstructive bronchitis\" more than once were defined as having asthma.

In Dresden and Munich, children underwent skin prick testing for six common aeroallergens (*Dermatophagoides pteronyssinus, D. farinae*, *Alternaria tenuis*, cat dander, and mixed grass and tree pollen) while in Leipzig *D. pteronyssinus*, grass, birch and hazel pollen, cat and dog dander was examined \[[@B10]\]. A positive skin reaction was defined as a wheal size ≥ 3 mm after subtraction of the negative control \[[@B9]\].

In the Munich and Dresden population, standard baseline lung function was measured and bronchial reactivity was assessed in a random 50% sub-sample of the study population by inhalation of nebulized, hyperosmolar saline (4.5%). Children with a drop in FEV~1~of 15% or more from baseline were classified as positive for bronchial hyperresponsiveness \[[@B9]\]. In the Leipzig population, measurements of airway challenges utilizing cold-air challenge were performed according to a previously published protocol \[[@B10]\]. In this case BHR was defined as a fall in FEV~1~of 9% corresponding to a value as large or larger than the 95th percentile of the reference population \[[@B11]\].

For this analysis, all children of German origin who had both DNA and IgE data available and had a doctor\'s diagnosis of asthma and/or showed BHR (N = 624, Munich n = 230, Dresden n = 263, Leipzig n = 131) were selected from the total study population. These children were matched at a 1:2 ratio with a random selection of healthy, non asthmatic, non atopic children without a diagnosis of BHR (Munich n = 460, Dresden n = 526, Leipzig n = 262) in the analysis.

Multicentre Allergy Study cohort
--------------------------------

The German Multicentre Allergy Study (MAS) cohort has been described in detail elsewhere \[[@B12],[@B13]\]. Initially, 1,314 children born in five German cities in the year 1990 were followed up from birth to the age of 13 years. For 888 children DNA was available and of these, only children of German origin were included in this study (n = 824). Yearly follow-up visits included standardized interviews, questionnaires, and physical examinations. In the MAS study, asthma, hay fever and atopic dermatitis at age 10 were defined using the ISAAC-core questions for children as described for the ISAAC study population.

Serum samples were obtained from the children at birth, and at 1, 2, 3, 5, 6, 7 and 10 years of age. Total IgE, specific IgE antibodies to food allergens and inhalant allergens (*Dermatophagoides pteronyssinus*, cat dander, mixed grass, birch pollen, as well as dog dander from age 3 years on) were determined by CAP-RAST FEIA (Pharmacia & Upjohn, Freiburg, Germany). In the MAS study, atopy was defined as a specific IgE level (CAP I) of ≥ 0.35 kU/l at age 7 or 10 years, respectively.

While pulmonary function tests were performed at age 7, 10 and 13, bronchial hyperresponsiveness was only assessed at age 7 in 610 individuals \[[@B14]\]. Bronchial challenges in the MAS study were conducted after baseline spirometry using increasing concentrations of histamine (usually from 0.5 mg/ml to 8.0 mg/ml) according to standard procedures. The 90^th^percentile of the distribution of PC~20~FEV~1~in a healthy subsample corresponded to 0.85 mg/ml. Bronchial hyperresponsiveness was defined as a PC~20~FEV~1~greater than this value.

Current environmental smoke exposure was defined as any current environmental tobacco smoke exposure at the age of the survey in ISAAC (9--11) and at the age 10-survey in MAS according to the information derived from parental questionnaires. *In utero*exposure to maternal smoking was assessed by a positive answer to the question \"Did the mother of the child smoke during pregnancy?\". Informed written consent was obtained from all parents of children included in the ISAAC and MAS studies. All study methods were approved by the local ethics committees.

Genotyping methods
------------------

For genotyping, the MassARRAY system (Sequenom, San Diego, USA) was used as previously described in detail \[[@B15]\]. All PCR reactions were performed using standard thermocyclers (MJ Research, Waltham, USA). First, a PCR was carried out. To remove excessive dNTPs, shrimp alkaline phosphatase was added to the PCR products. The base-specific extension reaction was performed in 10 μl reactions by Thermosequenase (Amersham, Piscataway, USA). For the base extension reaction the denaturation was performed at 94°C for 2 min, followed by 94°C for 5 sec, 52°C for 5 sec, and 72°C for 10 sec for 55 cycles. The final base extension products were treated with SpectroCLEAN resin to remove salts out of the reaction buffer, and 16 μl of water was added into each base extension reaction. After a quick centrifugation (2,000 rpm, 3 min) the reaction solution was dispensed onto a 384 format SpectroCHIP pre-spotted with a matrix of 3-hydroxypicolinic acid (3-HPA) by using a SpectroPoint nanodispenser. A modified Bruker Biflex matrix assisted laser desorption ionization-time-of-flight mass spectrometer was used for data acquisitions from the SpectroCHIP. Genotyping calls were made in real time with MASSARRAY RT software (Sequenom, San Diego, USA).

Statistical analysis
--------------------

Deviations from Hardy-Weinberg equilibrium were investigated for all polymorphisms using the χ^2^statistic, with expected frequencies derived from allele frequencies. Associations between SNPs and qualitative outcomes were determined using Cochran-Armitage-Trend-tests and χ^2^-tests in dominant models of the rare allele. Differences in lung function parameters were tested by univariate variance analysis and t-tests in dominant or recessive models.

Linkage Disequilibrium (LD) and the LD block structure were assessed using Haploview \[[@B16]\] and haplotype analysis was performed for all tagging SNPs after haplotype frequencies had been estimated by the EM (expectation-maximisation) algorithm \[[@B17]\]. Haplotype associations with asthma and BHR were calculated with the haplotype procedure in SAS/Genetics. In addition, haplotype trend regression models were estimated, where the estimated probabilities of the haplotypes were modelled in a logistic regression as independent variables \[[@B18]\].

For asthma as a binary outcome, logistic regression models for gene-environment interactions were used to estimate the combined effect of each SNP with exposure to environmental tobacco smoke (in utero and at time of survey). A Botto Khoury approach summarizing the data in a 2 × 4 table allowed for the evaluation of the independent and combined roles of genotype and exposure on disease risk \[[@B19]\].

All statistical analyses were carried out using the SAS statistical software package (Version 9.1) and the SAS/Genetics module.

Results
=======

Ten polymorphisms previously identified and showing associations in at least one replication study were selected for genotyping (table [1](#T1){ref-type="table"}). These SNPs, located in the 3\' half of the gene, spanned the known *ADAM33*linkage structure as indicated in figure [1](#F1){ref-type="fig"}. Call rates for SNPs in *ADAM33*ranged from 90.9% to 93.7% in the family based study population, from 92.1% to 94.3% in the case control population and from 91.9% to 94.0% in the pooled sample as indicated in table [1](#T1){ref-type="table"}. All SNPs were in Hardy Weinberg equilibrium in both populations. In the population based cross sectional study populations from East and West Germany, all SNPs showed allele frequencies similar to those previously published in other Caucasian populations (table [1](#T1){ref-type="table"}). Genotype frequencies and linkage disequilibrium were almost identical in both the case control population and the MAS cohort (data not shown).

###### 

Description of the investigated ADAM33 SNPs and assay conditions in the case control and cohort study population.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **position in original publication**   **rs numbers**   **Alleles**   **Minor Allele Frequency**   **PCR Primer**   **Extension Primer**                   **Callrate (%)**         
  -------------------------------------- ---------------- ------------- ---------------------------- ---------------- -------------------------------------- ------------------------ -------
  **F+1**                                rs511898         G/A           0.38                         0.36             fwd ACGTTGGATGAAAATACTGGGACTCGAGGC\    ACTCGAGGCCTGTGAATTCC     93.73
                                                                                                                      rev ACGTTGGATGTGCTGTATCTATAGCCCTCC                              

  **M+1**                                rs3918395        G/T           0.15                         0.13             fwd ACGTTGGATGGGGCACCAATTAACTAAGGC\    GCCGGCTCCCAAGCTCC        92.03
                                                                                                                      rev ACGTTGGATGTGAGGGCATGGAAGGTTCAG                              

  **S1**                                 rs3918396        G/A           0.09                         0.09             fwd ACGTTGGATGAGTCGGTAGCAACACCAGGC\    CCTGCTGGCCATGCTCCTCAGC   92.99
                                                                                                                      rev ACGTTGGATGAATCCCCGCAGACCATGACAC                             

  **S2**                                 rs528557         G/C           0.28                         0.28             fwd ACGTTGGATGAGTCGGTAGCAACACCAGG\     GCTGCCTCTGCTCCCAGG       91.88
                                                                                                                      rev ACGTTGGATGACCATGACACCTTCCTGCTG                              

  **ST+4**                               rs44707          A/C           0.41                         0.41             fwd ACGTTGGATGGGAGTGAAAAGATGTGCTGG\    ACAAATCACCTCTGTCACCC     92.58
                                                                                                                      rev ACGTTGGATGCCACTTCCTCTGCACAAATC                              

  **ST+5**                               rs597980         C/T           0.44                         0.45             fwd ACGTTGGATGAGAGAACTGGGTTAAGGCAG\    ACTCCATACCACTGGTCAGCTG   93.81
                                                                                                                      rev ACGTTGGATGCCAGCACATCTTTTCACTCC                              

  **ST+7**                               rs574174         G/A           0.19                         0.19             fwd ACGTTGGATGCTGCCCTTGATGATTCCAAG\    ACTGTCCCCATCCCATC        93.66
                                                                                                                      rev ACGTTGGATGGGAACATCACAGGAAATGAC                              

  **T1**                                 rs2280091        T/C           0.16                         0.14             fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC\   GGGCGGCGTTCACCCCA        93.77
                                                                                                                      rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG                              

  **T2**                                 rs2280090        C/T           0.16                         0.14             fwd ACGTTGGATGTTCCCTTCTCCCTTCCCTCTC\   CCCCACAGCCACTGGACAG      93.95
                                                                                                                      rev ACGTTGGATGTTGCTCAGCCCCAAAGATGG                              

  **V4**                                 rs2787094        C/G           0.22                         0.23             fwd ACGTTGGATGAGAAACAGGAAGGAAGGTCC\    CTGAGTCCACACTCCCCTG      93.84
                                                                                                                      rev ACGTTGGATGTATGGTTCGACTGAGTCCAC                              
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Single SNP analyses with qualitative traits
-------------------------------------------

Associations between *ADAM33*polymorphisms and the phenotypes asthma and BHR were investigated in both populations. As children in the case control sample were 9--11 years old at the time of disease status assessment and children in the longitudinal MAS study population were assessed using the same ISAAC core questions at age 10, all analyses of association with asthma in the MAS population were also performed at this and no other age. As BHR values were only available at age 7 but not at age 10 in the MAS population, BHR was analyzed separately in both populations.

No significant association could be detected between any tested SNP and doctor\'s diagnosed asthma, neither in the case control population nor in the cohort study, nor in the pooled dataset (table [2](#T2){ref-type="table"}). However, the risk to develop non atopic asthma (as defined as a doctor\'s diagnosis of asthma in the absence of a positive skin prick test) was increased in carriers of the polymorphic A allele in S1 (OR 1.53, 95%CI 1.01--2.31, p = 0.042) and in carriers of the polymorphic G allele in V4 (OR 1.44, 95%CI 1.03--2.01, p = 0.031). Furthermore, the risk for non atopic asthma was decreased in carriers of the polymorphic T allele for M+1 (OR = 0.60, 95%C.I. 0.40 -- 0.91, p = 0.016).

###### 

Odds ratios (OR) and 95% confidence intervals (95% CI) for the association between single *ADAM33*polymorphisms and asthma and BHR in the case-control population (age 9--11) and in the cohort study population assessed at age ten for asthma and age seven for BHR.

  ---------------------------------------------------------------------------------------------------------------------------------------------
               **Asthma**           **BHR^1^**           **Asthma and BHR^2^**                                             
  ------------ -------------------- -------------------- ----------------------- -------------------- -------------------- --------------------
  **SNP**      case-control study   cohort study         pooled                  case-control study   cohort study         case-control study

                                                                                                                           

  ***F+1***    0.92 (0.72--1.17)\   0.94 (0.58--1.52)\   0.92 (0.74--1.15)\      1.27 (0.96--1.69)\   1.01 (0.63--1.61)\   1.61 (0.90--2.88)\
               p = 0.502            p = 0.795            p = 0.478               p = 0.095            p = 0.962            p = 0.105

  ***M+1***    0.86 (0.65--1.13)\   0.94 (0.53--1.65)\   0.89 (0.70--1.14)\      1.18 (0.88--1.59)\   1.03 (0.61--1.74)\   1.46 (0.84--2.54)\
               p = 0.269            p = 0.819            p = 0.351               p = 0.274            p = 0.919            p = 0.177

  ***S1***     1.23 (0.90--1.69)\   1.16 (0.64--2.10)\   1.20 (0.90--1.58)\      1.27 (0.90--1.81)\   1.19 (0.67--2.14)\   1.10 (0.54--2.25)\
               p = 0.201            p = 0.635            p = 0.210               p = 0.175            p = 0.552            p = 0.789

  ***S2***     0.99 (0.78--1.26)\   0.97 (0.60--1.56)\   0.99 (0.80--1.22)\      1.29 (0.98--1.69)\   1.00 (0.63--1.59)\   1.72 (0.99--3.00)\
               p = 0.949            p = 0.893            p = 0.908               p = 0.073            p = 0.989            p = 0.052

  ***ST+4***   1.04 (0.81--1.34)\   1.31 (0.79--2.18)\   1.10 (0.87--1.37)\      0.99 (0.74--1.32)\   1.08 (0.67--1.74)\   1.22 (0.69--2.18)\
               p = 0.766            p = 0.292            p = 0.432               p = 0.956            p = 0.762            p = 0.490

  ***ST+5***   0.94 (0.73--1.22)\   0.80 (0.48--1.33)\   0.89 (0.71--1.12)\      0.95 (0.71--1.28)\   1.20 (0.71--2.00)\   0.91 (0.51--1.60)\
               p = 0.649            p = 0.384            p = 0.338               p = 0.748            p = 0.495            p = 0.731

  ***ST+7***   1.11 (0.86--1.42)\   1.16 (0.71--1.89)\   1.10 (0.88--1.38)\      1.20 (0.90--1.59)\   1.15 (0.72--1.84)\   0.96 (0.55--1.70)\
               p = 0.428            p = 0.549            p = 0.384               p = 0.209            p = 0.562            p = 0.901

  ***T1***     0.96 (0.74--1.25)\   0.92 (0.53--1.60)\   0.97 (0.76--1.23)\      1.20 (0.90--1.61)\   1.12 (0.67--1.88)\   1.50 (0.87--2.59)\
               p = 0.762            p = 0.764            p = 0.804               p = 0.213            p = 0.662            p = 0.141

  ***T2***     0.95 (0.73--1.24)\   0.88 (0.50--1.55)\   0.96 (0.76--1.22)\      1.21 (0.91--1.62)\   1.14 (0.68--1.91)\   1.51 (0.88--2.61)\
               p = 0.711            p = 0.666            p = 0.731               p = 0.196            p = 0.622            p = 0.134

  ***V4***     1.22 (0.95--1.55)\   0.82 (0.51--1.34)\   1.11 (0.90--1.38)\      1.13 (0.85--1.49)\   1.13 (0.71--1.78)\   1.31 (0.76--2.26)\
               p = 0.115            p = 0.439            p = 0.329               p = 0.402            p = 0.608            p = 0.332
  ---------------------------------------------------------------------------------------------------------------------------------------------

^1^No pooled analysis because of different techniques of BHR assessment in the case-control study and in the cohort study

^2^No analysis in the cohort study because of low number of cases

No significant association between *ADAM33*polymorphisms and BHR, assessed by histamine challenge in the MAS population at age 7 or with hypertonine saline inhalation or cold air challenge in the case control population at age 9--11, was observed as shown in table [2](#T2){ref-type="table"}. As the initial study by van Eerdewegh et al. \[[@B1]\] suggested the major effect of *ADAM33*polymorphisms in individuals with asthma and concomitant BHR, we investigated this specific phenotype in the case control population. Again, no SNP reached statistical significance in the association analysis (table [2](#T2){ref-type="table"}). As BHR values were only available at age 7 but not at age 10 in the MAS cohort study and different procedures were used to define BHR in both study populations, no combined analysis with both outcome variables was performed.

Single SNP analyses with lung function measurements
---------------------------------------------------

Next, the effects of *ADAM33*SNPs on baseline lung function measurements (FVC, FEV1, MEF25, MEF50 and MEF75) were investigated in cases (asthma and/or BHR positive) and controls separately (table [3](#T3){ref-type="table"}). In cases, FVC was increased in carriers of S2, T1 and T2 polymorphisms while FEV1 was increased in carriers of S2 and M+1 polymorphisms. In contrast to polymorphism S1, the presence of the polymorphic C allele in S2 increased the values for MEF75. In controls, negative effects on MEF50 were observed with ST+5 and MEF75 was increased in carriers of the M+1 or S2 SNP.

###### 

Lung function parameters in the case-control study for all cases \*)

  **SNP**                     **N**^1)^   **MEF~25~(%) Mean ± SD**   **MEF~50~(%) Mean ± SD**   **MEF~75~(%) Mean ± SD**   **FEV1 (%) Mean ± SD**   **FVC (%) Mean ± SD**
  ------------ -------------- ----------- -------------------------- -------------------------- -------------------------- ------------------------ -----------------------------
  ***F+1***    wild type      165         89.82 ± 29.66              89.47 ± 22.54              91.90 ± 16.28              97.65 ± 11.44            97.64 ± 11.03
               heterozygous   232         91.86 ± 32.06              91.22 ± 22.23              94.48 ± 18.53              99.32 ± 10.57            99.80 ± 10.02
               homozygous     64          92.61 ± 23.45              90.28 ± 17.19              97.32 ± 18.00              98.56 ± 10.75            98.16 ± 10.75
  ***M+1***    wild type      317         90.75 ± 30.97              89.70 ± 22.29              93.19 ± 17.82              **98.17 ± 11.43**\*^r^   98.12 ± 11.05
               heterozygous   128         91.28 ± 28.43              91.51 ± 22.15              95.56 ± 17.50              **99.01 ± 9.86**         99.86 ± 9.83
               homozygous     4           109.34 ± 23.03             98.95 ± 12.38              95.75 ± 23.07              **109.31 ± 9.13**        105.89 ± 9.71
  ***S1***     wild type      359         90.57 ± 30.08              90.00 ± 21.74              **93.23 ± 17.00**\*^v^     98.29 ± 10.86            98.46 ± 10.72
               heterozygous   86          94.29 ± 31.08              92.01 ± 24.43              **97.23 ± 21.03**          99.63 ± 11.23            99.58 ± 10.02
               homozygous     4           73.47 ± 16.07              76.17 ± 10.97              **78.46 ± 11.72**          90.84 ± 5.11             96.06 ± 1.40
  ***S2***     wild type      215         91.22 ± 31.50              89.69 ± 22.15              **92.14 ± 17.03**\*^d^     **97.50 ± 11.49**\*^d^   **96.97 ± 11.32**\*^v^\*^d^
               heterozygous   202         91.30 ± 29.78              91.43 ± 22.16              **96.12 ± 18.27**          **99.76 ± 10.73**        **100.55 ± 9.99**
               homozygous     31          95.31 ± 21.52              90.93 ± 22.04              **94.54 ± 20.57**          **99.55 ± 9.27**         **98.70 ± 9.25**
  ***ST+4***   wild type      158         90.05 ± 29.28              89.70 ± 22.41              93.18 ± 18.52              98.08 ± 10.38            99.09 ± 10.01
               heterozygous   223         92.00 ± 29.50              91.32 ± 22.23              94.83 ± 18.14              99.06 ± 11.75            98.61 ± 11.11
               homozygous     65          92.97 ± 34.91              90.22 ± 22.04              93.93 ± 14.12              98.68 ± 10.03            98.59 ± 11.39
  ***ST+5***   wild type      136         92.47 ± 31.51              91.10 ± 20.52              94.37 ± 15.25              99.26 ± 10.00            99.38 ± 10.88
               heterozygous   236         91.87 ± 29.26              91.02 ± 23.37              94.65 ± 19.04              98.79 ± 11.61            98.62 ± 10.58
               homozygous     88          87.50 ± 29.64              87.41 ± 20.55              91.39 ± 17.77              97.13 ± 10.41            98.48 ± 10.15
  ***ST+7***   wild type      285         90.28 ± 29.48              90.36 ± 21.92              93.30 ± 16.83              98.67 ± 10.93            99.10 ± 10.49
               heterozygous   158         94.26 ± 31.56              91.07 ± 22.55              94.99 ± 19.60              98.98 ± 11.11            98.63 ± 10.92
               homozygous     16          82.30 ± 24.76              82.94 ± 17.26              95.38 ± 16.31              93.87 ± 9.08             95.04 ± 7.62
  ***T1***     wild type      315         90.42 ± 31.04              89.55 ± 22.40              93.32 ± 17.78              98.07 ± 11.38            **98.12 ± 10.83**\*^d^
               heterozygous   135         92.59 ± 28.08              92.22 ± 21.39              95.50 ± 17.87              99.42 ± 9.78             **100.10 ± 9.98**
               homozygous     8           98.09 ± 27.48              90.95 ± 23.47              91.61 ± 19.64              103.91 ± 11.37           **103.30 ± 8.53**
  ***T2***     wild type      317         90.60 ± 31.04              89.61 ± 22.34              93.37 ± 17.71              98.13 ± 11.36            **98.14 ± 10.80**\*^d^
               heterozygous   135         92.59 ± 28.08              92.22 ± 21.39              95.50 ± 17.87              99.42 ± 9.78             **100.10 ± 9.98**
               homozygous     8           98.09 ± 27.48              90.95 ± 23.47              91.61 ± 19.64              103.91 ± 11.37           **103.30 ± 8.53**
  ***V4***     wild type      267         91.58 ± 30.15              89.98 ± 21.82              93.12 ± 17.14              98.24 ± 11.04            98.22 ± 10.82
               heterozygous   163         89.70 ± 30.05              89.71 ± 22.19              94.63 ± 18.60              98.57 ± 10.65            99.20 ± 10.23
               homozygous     26          95.52 ± 30.38              97.28 ± 24.60              96.90 ± 19.51              101.03 ± 11.93           99.82 ± 10.29

\*) significant differences (p \< 0.05) in lung function parameters between genotypes are printed in bold letters,

\*^v^denotes significant differences in variance analysis,

\*^d^denotes significant differences in t-test for a dominant model,

\*^r^significant differences in t-test for a recessive model

^1)^N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.

###### 

Lung function parameters in the case-control study for all controls \*)

  **SNP**                     **N**^1)^   **MEF~25~(%) Mean ± SD**   **MEF~50~(%) Mean ± SD**   **MEF~75~(%) Mean ± SD**   **FEV1 (%) Mean ± SD**   **FVC (%) Mean ± SD**
  ------------ -------------- ----------- -------------------------- -------------------------- -------------------------- ------------------------ -----------------------
  ***F+1***    wild type      291         98.48 ± 25.83              97.93 ± 19.80              99.22 ± 17.82              100.59 ± 9.86            98.28 ± 10.49
               heterozygous   348         101.46 ± 30.46             99.08 ± 21.41              100.69 ± 17.83             101.76 ± 10.29           99.08 ± 10.26
               homozygous     111         99.44 ± 29.96              99.63 ± 20.23              101.52 ± 19.80             101.38 ± 10.75           98.47 ± 10.38
  ***M+1***    wild type      522         99.25 ± 27.06              98.22 ± 20.12              **99.46 ± 17.92**\*^d^     101.06 ± 10.11           98.46 ± 10.51
               heterozygous   201         101.97 ± 32.25             100.01 ± 21.94             **102.51 ± 18.60**         102.10 ± 10.69           99.39 ± 10.29
               homozygous     12          95.45 ± 35.80              104.74 ± 19.55             **104.98 ± 13.31**         98.63 ± 8.56             96.65 ± 8.30
  ***S1***     wild type      627         100.12 ± 29.00             99.05 ± 20.58              100.58 ± 17.89             101.18 ± 10.28           98.67 ± 10.52
               heterozygous   116         98.23 ± 27.90              97.01 ± 21.40              99.16 ± 19.84              101.78 ± 10.41           99.29 ± 10.11
               homozygous     6           95.19 ± 21.20              98.62 ± 16.03              103.61 ± 13.45             103.74 ± 10.25           100.29 ± 11.22
  ***S2***     wild type      381         99.51 ± 26.91              98.44 ± 20.04              **98.82 ± 17.78**\*^d^     100.94 ± 10.08           98.34 ± 10.67
               heterozygous   292         101.59 ± 31.92             99.11 ± 22.33              **101.88 ± 18.68**         102.09 ± 10.56           99.55 ± 10.28
               homozygous     62          97.76 ± 25.55              100.37 ± 16.24             **101.35 ± 16.99**         102.51 ± 9.76            98.97 ± 9.91
  ***ST+4***   wild type      257         100.02 ± 28.64             98.04 ± 20.98              100.06 ± 17.63             101.58 ± 9.86            99.20 ± 9.75
               heterozygous   365         100.09 ± 28.74             99.28 ± 21.10              101.17 ± 19.05             101.39 ± 10.50           98.55 ± 10.50
               homozygous     114         98.52 ± 28.40              98.83 ± 18.79              98.41 ± 16.62              100.07 ± 10.09           98.18 ± 11.43
  ***ST+5***   wild type      222         100.79 ± 31.48             **101.33 ± 20.02**\*^d^    101.79 ± 17.87             101.33 ± 10.00           98.98 ± 10.29
               heterozygous   380         99.54 ± 28.10              **97.52 ± 21.27**          99.77 ± 18.20              100.85 ± 10.58           98.12 ± 10.82
               homozygous     148         99.48 ± 25.81              **97.72 ± 19.54**          99.23 ± 18.08              102.19 ± 9.46            99.74 ± 9.19
  ***ST+7***   wild type      507         100.34 ± 28.71             99.01 ± 20.67              100.26 ± 17.65             101.40 ± 10.17           98.93 ± 10.29
               heterozygous   213         98.76 ± 29.25              98.00 ± 20.58              100.11 ± 19.04             100.65 ± 9.99            98.01 ± 10.35
               homozygous     32          101.56 ± 24.74             98.45 ± 20.33              99.70 ± 19.21              103.37 ± 12.14           100.57 ± 12.16
  ***T1***     wild type      531         99.34 ± 27.07              98.23 ± 20.15              99.49 ± 18.08              101.07 ± 10.13           98.58 ± 10.53
               heterozygous   205         101.94 ± 32.34             99.58 ± 21.96              101.97 ± 18.39             101.81 ± 10.47           99.12 ± 10.14
               homozygous     15          95.29 ± 31.85              103.19 ± 18.07             101.58 ± 14.14             101.17 ± 9.28            98.59 ± 8.47
  ***T2***     wild type      532         99.31 ± 27.05              98.23 ± 20.13              99.51 ± 18.07              101.07 ± 10.12           98.57 ± 10.52
               heterozygous   204         102.01 ± 32.41             99.58 ± 22.01              101.92 ± 18.42             101.80 ± 10.49           99.09 ± 10.16
               homozygous     15          95.29 ± 31.85              103.19 ± 18.07             101.58 ± 14.14             101.17 ± 9.28            98.59 ± 8.47
  ***V4***     wild type      474         100.07 ± 28.66             98.91 ± 21.18              100.74 ± 18.35             101.32 ± 10.45           98.76 ± 10.49
               heterozygous   249         99.87 ± 29.37              98.91 ± 19.75              99.86 ± 17.75              101.62 ± 9.80            99.16 ± 10.07
               homozygous     35          99.31 ± 25.64              96.87 ± 19.30              100.16 ± 19.15             100.29 ± 11.81           96.95 ± 12.34

\*) significant differences in lung function parameters between genotypes are printed in bold letters,

\*^v^denotes significant differences in variance analysis,

\*^d^denotes significant differences in t-test for a dominant model,

\*^r^significant differences in t-test for a recessive model

^1)^N refers to the first lung function parameter. Minimal deviations of N in the other lung function parameters are possible.

Haplotype analysis
------------------

In a further step, haplotypes were estimated in both populations for all samples genotyped successfully for at least one *ADAM33*SNP (1,802 in the case control population and 782 in the MAS cohort) using the EM algorithm. The estimated frequencies of all common *ADAM33*haplotypes built from the eight SNPs F+1, S1, S2, ST+4, ST+5, ST+7, T1 and V4 and all ten SNPs are presented in table [4](#T5){ref-type="table"}. As SNPs M+1, T1 and T2 were in extremely tight linkage disequilibrium, polymorphisms M+1 and T2 contributed no additional information to the haplotype and thus were excluded from the further haplotype building procedure.

###### 

Estimated frequencies of common haplotypes in different German populations

                                                                                                               **Estimated frequencies in the different populations^3^**                            
  ------------- --------- -------- -------- -------- --------- ---------- ---------- -------- ------- -------- ----------------------------------------------------------- ------------------------ ------------------
                **F+1**   M+1^2^   **S1**   **S2**   **ST4**   **ST+5**   **ST+7**   **T1**   T2^2^   **V4**   **pooled**                                                  **case-control study**   **cohort study**
                                                                                                                                                                                                    
  **H1**        **G**     G        **G**    **G**    **A**     **T**      **G**      **T**    C       **C**    31.59% (31.62%)                                             31.42% (31.43%)          32.21% (32.24%)
  **H2**        **G**     G        **G**    **G**    **C**     **C**      **G**      **T**    C       **C**    16.63% (16.66%)                                             16.66% (16.67%)          16.54% (16.62%)
  **H3**        **A**     T        **G**    **C**    **A**     **C**      **G**      **C**    T       **C**    14.00% (13.91%)                                             14.67% (14.67%)          12.50% (12.20%)
  **H4**        **G**     G        **G**    **G**    **C**     **C**      **G**      **T**    C       **G**    11.22% (11.20%)                                             11.02% (11.01%)          11.48% (11.48%)
  **H5**        **A**     G        **A**    **C**    **A**     **T**      **A**      **T**    C       **G**    7.84% (7.84%)                                               7.73% (7.73%)            8.12% (8.12%)
  **H6**        **A**     G        **G**    **G**    **C**     **C**      **A**      **T**    C       **C**    6.48% (6.50%)                                               6.68% (6.70%)            6.06% (6.07%)
  **Rare^1^**                                                                                                  12.24% (12.28%)                                             11.82% (11.80%)          13.10% (13.27%)

^1)^Rare are all haplotypes with an estimated frequency \< 0.03 in the pooled sample

^2)^SNPs which are excluded after choosing only tagging SNPs

^3)^Estimated frequencies of the 8-SNP-haplotype, in brackets estimated frequencies of the 10-SNP-haplotype

One common haplotype, H4 (G-G-G-C-C-G-T-G), showed a weak but not significant association with asthma in the case control population but not in the cohort as indicated in table [5a](#T6){ref-type="table"}. This association became significant in the pooled analysis. No association was found with BHR (data not shown). When a haplotype trend regression was performed for the haplotype H4, an OR of 1.57 (95%CI 0.99--2.51, p = 0.057) in the pooled population was observed.

###### 

Estimated haplotype frequencies and associations with asthma in case control and cohort populations

       **Haplotype**         **Study population**^1)^   **Haplotype frequencies in the cases**   **Haplotype frequencies in the controls**   **Odds Ratio and Confidence intervals**^2)^   **p-value of χ^2^-Test**
  ---- --------------------- -------------------------- ---------------------------------------- ------------------------------------------- --------------------------------------------- --------------------------
  H1   **G-G-G-A-T-G-T-C**   **all**                    30.35%                                   32.21%                                      0.92(0.78--1.08)                              0.293
                             **ccs**                    30.90%                                   31.56%                                      0.97(0.81--1.15)                              0.735
                             **coh**                    30.03%                                   34.02%                                      0.83(0.58--1.19)                              0.317
  H2   **G-G-G-C-C-G-T-C**   **all**                    17.02%                                   16.69%                                      1.02(0.84--1.25)                              0.804
                             **ccs**                    16.77%                                   16.85%                                      0.99(0.80--1.24)                              0.939
                             **coh**                    16.93%                                   16.32%                                      1.04(0.67--1.63)                              0.847
  H3   **A-G-C-A-C-G-C-C**   **all**                    12.98%                                   14.08%                                      0.91(0.73--1.13)                              0.402
                             **ccs**                    13.60%                                   14.85%                                      0.90(0.71--1.15)                              0.406
                             **coh**                    10.33%                                   12.04%                                      0.84(0.49--1.45)                              0.531
  H4   **G-G-G-C-C-G-T-G**   **all**                    12.96%                                   10.44%                                      1.28(1.02--1.60)                              0.033
                             **ccs**                    13.15%                                   10.65%                                      1.27(0.99--1.64)                              0.063
                             **coh**                    11.43%                                   9.85%                                       1.18(0.70--2.00)                              0.528
  H5   **A-A-C-A-T-A-T-G**   **all**                    8.35%                                    7.69%                                       1.09(0.83--1.43)                              0.517
                             **ccs**                    8.62%                                    7.16%                                       1.22(0.90--1.66)                              0.191
                             **coh**                    7.18%                                    9.07%                                       0.78(0.41--1.46)                              0.430
  H6   **A-G-G-C-C-A-T-C**   **all**                    6.70%                                    6.54%                                       1.03(0.76--1.38)                              0.867
                             **ccs**                    6.17%                                    6.67%                                       0.92(0.65--1.30)                              0.638
                             **coh**                    8.99%                                    6.19%                                       1.50(0.82--2.72)                              0.184

^1)^All = case control study and cohort study population pooled, ccs = case control study (n = 358 cases/n = 1198 controls), coh = cohort study (n = 82 cases/n = 464 controls); children without haplotype information were excluded

^2)^Odds Ratios were calculated as one haplotype vs. all others

Gene environment interaction analysis
-------------------------------------

As it was hypothesised that ADAM33 could influence the effects of passive smoke exposure on asthma, BHR or lung function, gene environment interactions were assessed using a Botto Khoury approach. However, no such interactions could be detected (data not shown).

Discussion
==========

We have genotyped 2,696 subjects including more than 700 children with asthma and/or BHR for 10 SNPs in the *ADAM33*gene. For doctor\'s diagnosed asthma, no SNP showed a significant association in any of the analyzed populations. A trend for somewhat more profound but not significant effects of *ADAM33*SNPs was observed in individuals with asthma and BHR, for which trait the most significant association results were reported in the original study on *ADAM33*. However, in the case control population, these associations did just not reach statistical significance. Haplotype analyses suggested a minor effect of the *ADAM33*haplotype H4 on asthma but not BHR. A number of individual SNPs showed an association with non atopic asthma in the case control population. A diverse picture evolved when the effects of *ADAM33*polymorphisms on baseline lung function were measured. However, these associations did not remain significant after correction for multiple testing. No interaction with passive smoke exposure could be detected.

*ADAM33*was the first published candidate gene for asthma identified by positional cloning. In the initial report 37 SNPs in the *ADAM33*gene have been identified and 15 polymorphisms have been genotyped in a UK and a US study population \[[@B1]\]. Even within these two populations, different SNPs were associated with asthma and BHR. Associations were significantly stronger in those cases additionally showing BHR, suggesting that ADAM33 acts via lung specific mechanisms. A putatively functional role for ADAM33 in the pathogenesis of asthma has been hypothesised as ADAM33 is expressed in smooth muscle cells of the bronchial and vascular system in the lung \[[@B1],[@B20]\]. It has been speculated that ADAM33 may act as a protease activating cytokine or induce airway smooth muscle proliferation. ADAM33 and its so far identified polymorphisms may have less to do with atopic inflammation and more with non atopic lung specific forms of asthma. To a somewhat lesser degree, this initial BHR effect was confirmed in our study population.

In terms of replication on a population level, the role of *ADAM33*SNPs in asthma remains controversial. It seems that even the studies reporting a positive association between *ADAM33*SNPs and atopic phenotypes are inhomogeneous in their findings (table [6](#T7){ref-type="table"}). These inconsistencies in replication may have different reasons. They could be due to population heterogeneity, as some studies may suggest. Howard and co-workers genotyped 8 SNPs in 4 different ethnical populations (Dutch, white Americans, Hispanics and African Americans) and found a wide variety of associations between the different ethnical groups and various *ADAM33*SNPs \[[@B4]\]. No single SNP was associated with asthma in all 4 groups and when corrected for multiple testing, only one association remained significant. In studies of asthmatics with a Hispanic background, no association with *ADAM33*SNPs was observed with asthma \[[@B21]\]. Thus, differences in haplotype structure or even in the occurrence of SNPs may exist between ethnicities, which have not yet been investigated sufficiently for *ADAM33*but which are known to exist for a number of other genes.

###### 

Comparison of previously reported association results^1^with *ADAM33*polymorphisms

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Study**                  **Study population**      **N^2^**                         ***ADAM33*SNPs and reported associations**                                                                                                                                                           
  -------------------------- ------------------------- -------------------------------- -------------------------------------------- -------- --------- --------- --------- -------- ---------- ---------- ---------- ---------- ---------- ---------- -------- --------- --------- -------- --------
                             cc = case control\        cases/controls families (ind.)   **F+1**                                      **I1**   **L-1**   **M+1**   **Q-1**   **S1**   **S2**     **ST+1**   **ST+4**   **ST+5**   **ST+7**   **T1**     **T2**   **T+1**   **V-1**   **V1**   **V4**
                             fa = family study                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                                             

  **Van Eerdewegh et al**.   US/UK combined (cc)       130/217                          neg                                          neg      neg       neg       A         A        neg        neg        A          neg        A          neg        neg      neg       A         neg      A

                             UK (cc)                   (not reported)                   A                                            neg      neg       neg       A         A        A          neg        A          neg        neg        neg        neg      neg       A         neg      A

                             US (cc)                   (not reported)                   neg                                          A        A         A         neg       neg      neg        neg        neg        neg        neg        A          A        A         neg       neg      neg

                             US/UK (fa)                460fa (1840)                                                                                                         A                                                               B                             neg       neg      neg

                                                                                                                                                                                                                                                                                             

  **Lind et al**.            Mexican (cc)              190/160                                                                                                              neg                                                             neg        neg                neg       neg      neg

                             Puerto Rican (cc)         183/165                                                                                                              neg                                                             neg        neg                neg       neg      neg

                             Mexican/P. Rican (fa)     583fa (1749)^3^                                                                                                      neg                                                             neg        neg                neg       neg      neg

                                                                                                                                                                                                                                                                                             

  **Raby et al.^4^**         Non-Hispanic white (fa)   474 (1462)                                                                                       neg                          neg                   neg        neg                   neg        neg      neg       neg                neg

                             Hispanic (fa)             47 (149)                                                                                         neg                          neg                   neg        neg                   A          neg      A         neg                neg

                             African American (fa)     66 (203)                                                                                         neg                          neg                   neg        neg                   neg        neg      neg       neg                neg

                                                                                                                                                                                                                                                                                             

  **Werner et al**.          German (cc)               48/499                           neg                                          neg                neg       neg       neg      neg        neg        neg        B          A          neg        neg      neg       neg                neg

                             German (fa)               171fa (732)                      A, B, AB                                     neg                neg       neg       neg      B, AB      neg        A          A          neg        neg        neg      neg       neg                neg

                                                                                                                                                                                                                                                                                             

  **Howard et. al**.         African American (cc)     161/265^5^                                                                                                           neg      A                     AT                    neg        neg        neg                neg                AT

                             US White (cc)             220/229^5^                                                                                                           neg      A^6^, AT              neg                   A          A, AT      A, AT              neg                neg

                             US Hispanic (cc)          113/127^5^                                                                                                           neg      A                     AT                    neg        A^6^, AT   A, AT              AT                 neg

                             Dutch White (cc)          180/133^5^                                                                                                           AT       AT                    neg                   A, AT      neg        neg                AT                 A

                                                                                                                                                                                                                                                                                             

  **Blakey et al**.          Icelandic (cc)            348/262                          neg                                                             neg       neg       neg      neg                   neg        neg        neg        neg        neg      neg       neg                neg

                             Nottingham (fa)           60fa (240)                       neg                                                             neg       neg       neg                            neg        neg        neg        neg        neg      neg       neg       neg      neg
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^association with asthma (= A), BHR (= B), Asthma and BHR (= AB) or Atopy (= AT) in different studies; SNPs which are not significantly associated = neg

^2^in case-control studies number of cases and controls, in family studies number of families and individuals

^3^265 Mexican families and 318 Puerto Rican families, no association neither in single nor in pooled population

^4^in the study of Raby et al. 8 additional SNPs were investigated: G1, I1, KL+3, N1, S+1, T+2, V-2, V3. None of the additional SNPs showed an association with asthma.

^5^N is reported as maximum number of successfully genotyped subjects

^6^only a trend (0.05 \< p ≤ 0.06)

A further explanation for the differences in replication results might be that the definition of asthma may have varied between studies. As ADAM33 may specifically affect remodeling of the lungs, the impact of genetic variations in ADAM33 could be variable in different forms of asthma. In other words, *ADAM33*genetics may have more impact on those forms of asthma which are less driven by atopy and more associated with lung specific mechanisms. Our data indeed suggests that the known *ADAM33*SNPs have only a minor impact on the most common form of childhood asthma, which is highly correlated with atopy in most study populations. In contrast, a number of *ADAM33*SNPs were associated with non atopic asthma as well as baseline lung function measurements in our study. However, the pattern of association remains complex as different SNPs are associated with non atopic asthma and determinants of lung function. Moreover, *ADAM33*SNPs also seem to play a different role in adult asthma than in childhood asthma as indicated by previously published studies. Werner et al. genotyped 15 *ADAM33*SNPs in a family based and in an adult case control population and observed variable associations between SNPs and asthma within the two populations and also in respect to the initially reported associations \[[@B7]\]. Very large studies investigating childhood asthma by Lind \[[@B21]\] and Raby \[[@B6]\] could not find any association between single *ADAM33*SNPs or haplotypes and childhood asthma. However, no analyses of *ADAM33*effects on non atopic asthma have been reported in these studies of childhood asthma. While Raby et al. \[[@B6]\] stated that it seems very unlikely that these negative studies were underpowered to detect an association, a recent meta analysis suggested, that the odds ratio for the ADAM33 locus may be in the order of 1.4 or lower for SNPs known to date \[[@B3]\]. Even with large data sets such as used in this study, the ability to detect risks of this magnitude may be limited. Furthermore, it may be possible that the known SNPs in ADAM33 are only a proxy for additional, yet unidentified SNPs in the ADAM33 gene, which could be the true cause for the observed but mixed signals from this locus.

Finally, differences in the study populations in terms of gene by environment interactions may also explain some of the observed discrepancy in replication as has been suggested to be the case with other genes inconsistently replicated \[[@B22],[@B23]\]. However, it is not clear, which environmental factors may interact with *ADAM33*genetics and if these factors could influence the associations between *ADAM33*polymorphisms and asthma. As indicated by our analysis, passive smoke exposure does not seem to be one of these factors.

In the meantime, a total of five genes (*ADAM33*\[[@B1]\], *PHF11*\[[@B24]\], *DPP10*\[[@B25]\]*GPRA*\[[@B26]\] and *HLA-G*\[[@B27]\] have been proposed as potential asthma genes by positional cloning and some more may follow. What can we learn from the experience with *ADAM33*? First, it seems that genes identified by positional cloning have the same limitations as other putative candidate genes suggested by expression studies, or selected because of their biological context in disease pathways. Positional cloning does not prove but suggest a role of the gene in question for a specific disease. Further evidence however can only be achieved by independent replication studies and functional molecular genetics, which both may be tedious. This process may take some time and the level of evidence for or against the involvement of a certain gene in a complex disease may only increase with time. Large and well defined replications are needed and negative results ought to be published.

Conclusion
==========

Our data suggest that previously reported *ADAM33*polymorphisms may only have a minor impact on the development of asthma in German children.

Abbreviations
=============

ADAM33 a disintegrin and metalloprotease 33

BHR bronchial hyperresponsiveness

EM expectation-maximisation

FEV1 forced expiratory volume in one second

FVC forced vital capacity

IgE immunoglobulin E

ISAAC II International Study of Asthma and Allergy in Childhood

LD linkage disequilibrium

MAS Multicentre Allergy Study

MALDI-TOF Matrix-assisted laser desorption time of flight

MEF maximum expiratory flow

OR odds ratio

PC~20~Provocative concentration inducing a 20% fall in FEV1

PCR polymerase chain reaction

SNP single nucleotide polymorphism
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